Subsequently, Taar1 was considered as a drug target for treatment of alcohol and drug addiction, as well as Parkinson’s disease and schizophrenia (Bradaia et al., 2009; Galley et al., 2012; Revel et al., 2012b; Lynch et al., 2013; Alvarsson et al., 2015; reviewed in Grandy, 2007, 2014; Grandy et al., 2016; Berry et al., 2017). This evidence concerns the gene TAAR1 and Parkinson disease.